Carnosic Acid Improves Outcome after Repetitive Mild Traumatic Brain Injury
Abstract
In the majority of cases, the cognitive and behavioral impairments resulting from a mild traumatic brain injury (TBI) (also referred to as concussion) wane within days to weeks. In contrast, these impairments can persist for months to years after repetitive mild TBI (rmTBI). The cellular and molecular mechanisms underlying these impairments are not well understood. In the present study, we examined the consequences of rmTBI (three weight drops each separated by 72 h) on brain tissue respiration, pathology, and cognitive performance in mice. The transcription factor nuclear factor-erythroid 2-realted factor 2 (Nrf2) has been demonstrated to enhance the expression of numerous cytoprotective genes. Carnosic acid (CA) has been shown to activate Nrf2 and suppress the proinflammatory transcription factor nuclear factor kappa B (NF-κB). Because contemporaneous activation of cytoprotective genes and inhibition of proinflammatory genes can be beneficial, we questioned whether CA can be used to mitigate the pathobiology of rmTBI. The rmTBI increased hippocampal adenosine triphosphate-linked tissue respiration and proton leak that were unaffected by CA treatment. The rmTBI also caused significant motor and cognitive dysfunction, as tested using the foot fault, Barnes maze, and novel object recognition tasks. These impairments occurred in the absence of visible neuronal or dendritic loss. Post-rmTBI administration of CA significantly improved motor and cognitive function, and decreased Gfap and Iba1 immunoreactivities within white matter tracks. Taken together, these results show that rmTBI can cause cognitive impairments in the absence of overt neuronal pathologies, and post-injury treatment with CA can lessen some of these impairments.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Fidan E., Lewis J., Kline A.E., Garman R.H., Alexander H., Cheng J.P., Bondi C.O., Clark R.S., Dezfulian C., Kochanek P.M., Kagan V.E., and Bayir H. (2016). Repetitive mild traumatic brain injury in the developing brain: effects on long-term functional outcome and neuropathology. J. Neurotrauma 33, 641–651.
2. Mouzon B.C., Bachmeier C., Ojo J.O., Acker C.M., Ferguson S., Paris D., Ait-Ghezala G., Crynen G., Davies P., Mullan M., Stewart W., and Crawford F. (2018). Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury. Ann. Clin. Transl. Neurol. 5, 64–80.
3. Manley G., Gardner A.J., Schneider K.J., Guskiewicz K.M., Bailes J., Cantu R.C., Castellani R.J., Turner M., Jordan B.D., Randolph C., Dvorak J., Hayden K.A., Tator C.H., McCrory P., and Iverson G.L. (2017). A systematic review of potential long-term effects of sport-related concussion. Br. J. Sports Med. 51, 969–977.
4. Hayes J.D. and Dinkova-Kostova A.T. (2014). The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39, 199–218.
5. Zhao J., Kobori N., Aronowski J., and Dash P.K. (2006). Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci. Lett. 393, 108–112.
6. Zhao J., Moore A.N., Redell J.B., and Dash P.K. (2007). Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J. Neurosci. 27, 10240–10248.
7. Lipton S.A., Rezaie T., Nutter A., Lopez K.M., Parker J., Kosaka K., Satoh T., McKercher S.R., Masliah E., and Nakanishi N. (2016). Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. Cell Death Dis. 7, e2499.
8. Ma Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53, 401–426.
9. Mimura J., Kosaka K., Maruyama A., Satoh T., Harada N., Yoshida H., Satoh K., Yamamoto M., and Itoh K. (2011). Nrf2 regulates NGF mRNA induction by carnosic acid in T98G glioblastoma cells and normal human astrocytes. J. Biochem. 150, 209–217.
10. Aruoma O.I., Spencer J.P., Rossi R., Aeschbach R., Khan A., Mahmood N., Munoz A., Murcia A., Butler J., and Halliwell B. (1996). An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provencal herbs. Food Chem. Toxicol. 34, 449–456.
11. Schwager J., Richard N., Fowler A., Seifert N., and Raederstorff D. (2016). Carnosol and related substances modulate chemokine and cytokine production in macrophages and chondrocytes. Molecules 21, 465.
12. Miller D.M., Singh I.N., Wang J.A., and Hall E.D. (2015). Nrf2-ARE activator carnosic acid decreases mitochondrial dysfunction, oxidative damage and neuronal cytoskeletal degradation following traumatic brain injury in mice. Exp. Neurol. 264, 103–110.
13. Marmarou A., Foda M.A., van den Brink W., Campbell J., Kita H., and Demetriadou K. (1994). A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J. Neurosurg. 80, 291–300.
14. Kalish B.T. and Whalen M.J. (2016). Weight drop models in traumatic brain injury. Methods Mol. Biol. 1462, 193–209.
15. Vagnozzi R., Tavazzi B., Signoretti S., Amorini A.M., Belli A., Cimatti M., Delfini R., Di Pietro V., Finocchiaro A., and Lazzarino G. (2007). Temporal window of metabolic brain vulnerability to concussions: mitochondrial-related impairment—part I. Neurosurgery 61, 379–388.
16. Tavazzi B., Vagnozzi R., Signoretti S., Amorini A.M., Belli A., Cimatti M., Delfini R., Di Pietro V., Finocchiaro A., and Lazzarino G. (2007). Temporal window of metabolic brain vulnerability to concussions: oxidative and nitrosative stresses—part II. Neurosurgery 61, 390–395.
17. Dash P.K., Hylin M.J., Hood K.N., Orsi S.A., Zhao J., Redell J.B., Tsvetkov A.S., and Moore A.N. (2015). Inhibition of eukaryotic initiation factor 2 alpha phosphatase reduces tissue damage and improves learning and memory after experimental traumatic brain injury. J. Neurotrauma 32, 1608–1620.
18. Prins M.L., Hales A., Reger M., Giza C.C., and Hovda D.A. (2010). Repeat traumatic brain injury in the juvenile rat is associated with increased axonal injury and cognitive impairments. Dev. Neurosci. 32, 510–518.
19. Davis A.R., Shear D.A., Chen Z., Lu X.C., and Tortella F.C. (2010). A comparison of two cognitive test paradigms in a penetrating brain injury model. J. Neurosci. Methods 189, 84–87.
20. Lafrenaye A.D., Todani M., Walker S.A., and Povlishock J.T. (2015). Microglia processes associate with diffusely injured axons following mild traumatic brain injury in the micro pig. J. Neuroinflammation 12, 186.
21. Floyd C.L. and Lyeth B.G. (2007). Astroglia: important mediators of traumatic brain injury. Prog. Brain Res. 161, 61–79.
22. Hubbard W.B., Harwood C.L., Geisler J.G., Vekaria H.J., and Sullivan P.G. (2018). Mitochondrial uncoupling prodrug improves tissue sparing, cognitive outcome, and mitochondrial bioenergetics after traumatic brain injury in male mice. J. Neurosci. Res. 96, 1677–1688.
23. Bains M. and Hall E.D. (2012). Antioxidant therapies in traumatic brain and spinal cord injury. Biochim. Biophys. Acta 1822, 675–684.
24. Fischer T.D., Hylin M.J., Zhao J., Moore A.N., Waxham M.N., and Dash P.K. (2016). Altered mitochondrial dynamics and TBI pathophysiology. Front. Syst. Neurosci. 10, 29.
25. Kochanek P.M., Jackson T.C., Ferguson N.M., Carlson S.W., Simon D.W., Brockman E.C., Ji J., Bayir H., Poloyac S.M., Wagner A.K., Kline A.E., Empey P.E., Clark R.S., Jackson E.K., and Dixon C.E. (2015). Emerging therapies in traumatic brain injury. Semin. Neurol. 35, 83–100.
26. Xiong Y., Gu Q., Peterson P.L., Muizelaar J.P., and Lee C.P. (1997). Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J. Neurotrauma 14, 23–34.
27. Lyons D.N., Vekaria H., Macheda T., Bakshi V., Powell D.K., Gold B.T., Lin A.L., Sullivan P.G., and Bachstetter A.D. (2018). A mild traumatic brain injury in mice produces lasting deficits in brain metabolism. J. Neurotrauma 20, 2435–2447.
28. de Oliveira M.R., Peres A., Ferreira G.C., Schuck P.F., Gama C.S., and Bosco S.M. (2017). Carnosic acid protects mitochondria of human neuroblastoma SH-SY5Y cells exposed to paraquat through activation of the Nrf2/HO-1 axis. Mol. Neurobiol. 54, 5961–5972.
29. Miller D.M., Singh I.N., Wang J.A., and Hall E.D. (2013). Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo. Free Radic. Biol. Med. 57, 1–9.
30. Yanagitai M., Itoh S., Kitagawa T., Takenouchi T., Kitani H., and Satoh T. (2012). Carnosic acid, a pro-electrophilic compound, inhibits LPS-induced activation of microglia. Biochem. Biophys. Res. Commun. 418, 22–26.
31. Villapol S., Loane D.J., and Burns M.P. (2017). Sexual dimorphism in the inflammatory response to traumatic brain injury. Glia 65, 1423–1438.
32. Caplan H.W., Cox C.S., and Bedi S.S. (2017). Do microglia play a role in sex differences in TBI? J. Neurosci. Res. 95, 509–517.
Information & Authors
Information
Published In

Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers.
History
Published in print: July 1, 2019
Published online: 27 June 2019
Published ahead of print: 26 March 2019
Published ahead of production: 23 January 2019
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.